<DOC>
	<DOCNO>NCT00846482</DOCNO>
	<brief_summary>This study patient advance stage II III colon rectal cancer . The primary purpose research study determine particular protein patient 's blood change receive treatment drug call oxaliplatin , use treat colon rectal cancer . This protein call ERCC-1 . It think amount protein blood could influence manner patient responds oxaliplatin .</brief_summary>
	<brief_title>Exploratory Study Of The ERCC-1 Gene</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically confirm diagnosis colorectal cancer . ECOG Performance Status 02 ( Appendix A ) . Patient candidate oxaliplatin base therapy either adjuvant metastatic setting . Consent donate 4 tube PBMC 7 ml blood . Willing consider additional post therapy tumor biopsy applicable ( refusal consent exclusion criterion ) . Adequate organ function define : Neutrophil count &gt; 1500/μl Platelets &gt; 75,000/ μl Hemoglobin &gt; 8 g/dl Bilirubin &lt; 2.0 X upper limit normal Creatinine &lt; 2 mg % calculated clearance &gt; 40 ml/mt The patient must sign consent form approve Albert Einstein College Medicine Cancer Center CCI Montefiore Medical Center IRB No significant underlie medical condition , opinion principal investigator designees , make administration oxaliplatin unusually hazardous , significant hepatic , bone marrow and/or cardiac disease , require active medical treatment . Pregnant woman woman child bear potential practice birth control sexually active male unwilling practice contraception study . Patients undergo major surgical procedure ( delay enrollment complete recovery surgery 4 wk major 2 wk minor surgery ) . Patients grade 2 neuropathy eligible study . The patient must receive chemotherapy within 4 week begin oxaliplatin treatment . At least 6 week must elapse prior therapy include mitomycin C nitrosoureas . At least 2 week must elapse since end prior palliative radiation therapy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>ERCC-1</keyword>
</DOC>